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DEGREES OF RECOMMENDATION AND EVIDENCE STRENGTH:
A: Experimental or observational studies of better con-
sistency.
B: Experimental or observational studies of lesser con-
sistency.
C: Case reports (non-controlled studies).
D: Opinion without critical evaluation, based on con-
sensus, and on physiological or animal models studies.
CONCEPT AND EPIDEMIOLOGY
Crohn’s disease is a chronic inflammatory process of un-
known etiology affecting the gastrointestinal tract, uni- or 
multifocal, of variable severity, transmural1, and it is not 
curable by clinical or surgical treatment (C)2,3 (D). The 
small and large intestines are affected more often. Perianal 
manifestations can be seen in more than 50% of the pa-
tients1 (C). Associated or isolated extraintestinal manifes-
tations can occur, affecting the skin, joints, eyes, liver, and 
urinary tract more commonly4 (B)5 (D). The disease affects 
individuals of any age, but the diagnosis is more common 
in the second or third decades6 (D).
DIAGNOSIS
The diagnosis of Crohn’s disease results of the analysis of 
clinical (anamnesis, and complete physical and proctolog-
ic exams), endoscopic, radiologic, laboratorial, and histo-
logical data2 (D). Clinical manifestations are more com-
monly of an inflammatory, obstructive, and/or fistulizing 
nature, which carry greater or lower prognostic value7 (D). 
Symptoms of chronic diarrhea, abdominal pain, weight 
loss, and rectal bleeding direct the anamnesis. Clinical 
signs include malnutrition, cutaneous-mucous parlor, 
pain, abdominal mass, and distension or fistulization into 
the abdominal wall. Proctologic exam can be positive for 
anal fissure(s), edematous anal plicomas, fistulae, and cel-
lulitis or abscesses and can, initially, be isolated, as well as 
extraintestinal manifestations1 (C)2 (D).
Toxic and acute colon dilation (toxic megacolon) is an 
acute and severe, but uncommon presentation8 (B). The 
presentation of diarrhea requires differential diagnosis 
with infectious colitis (viral or bacterial) and protozoal 
bowel disorders. Acute ileitis requires differential diag-
nosis with acute appendicitis. The differential diagnosis 
of Crohn’s disease includes ulcerative rectocolitis9 (B). In 
up 20% of the cases, once current available investigative 
resources are exhausted, a diagnosis is not possible, be-
ing classified as undetermined colitis10 (D). The diagnosis 
of intestinal Crohn’s disease also requires the differential 
diagnosis with other enterocolitis (ischemic, actinic, or 
antibiotic-induced) and with irritable bowel disease6 (D).
The most common extraintestinal manifestations are 
directly related to the inflammatory bowel process, and 
they can affect the skin (erythema nodosum and gangre-
nous pyoderma), peripheral (arthritis) or axial (ankylos-
ing spondylitis and sacroiliitis) joints, eyes (conjunctivitis 
and uveitis), and liver (primary sclerosing cholangitis). 
Cholecystolithiasis and nephrolithiasis can also result 
from malabsorption1 (C).
Contrast-enhanced exams (intestinal transit, bar-
ium enema, and double contrast study) are necessary to 
confirm the location and extent, as well as diagnosis, of 
complications. Barium-enhanced exams should not be 
performed in acutely ill patients or those who require 
hospitalization. Ultra-sound of the abdomen and com-
puterized tomography (CT) should be performed, pref-
erentially, during crisis or exacerbations, in the presence 
of abdominal mass, or suspected abscess. Besides, those 
exams are useful in the evaluation of abdominal and pelvic 
complications. They can be useful in preoperative planning 
and also to guide punctures. Magnetic resonance imaging 
(MRI) can be used in patients who are allergic to iodinated 
contrast and in gravidas, and it seem to make a difference in 
the evaluation of anorectal disease in some studies. High-
resolution MRI has good accuracy in detecting anal fistulae 
in Crohn’s diseases, providing important information for 
preoperative planning of recurring fistulae11 (B). X-Rays of 
the abdomen should be performed to evaluate patients with 
acute abdomen or suspicion of toxic megacolon12,13 (D).
Colonoscopy is used to confirm the clinical suspicion 
of Crohn’s disease and to obtain biopsies. Endoscopy is 
more sensitive than contrast-enhanced exams regarding 
extension of the disease. When a strong suspicion of coli-
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Crohn’s Disease Activity Index
Number of liquid stools (daily for 7 days) x 2
Abdominal pain (none = 0, mild = 1, moderate = 2, severe = 3) x 5
Sense of well-being (well = 0, slightly below par = 1, poor = 2, very poor = 4, terrible = 4) x 7
Number of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum, aphthous 
stomatitis, anal fissure/fistula or abscess, fever > 37.8° C) x 20
Taking diphenoxylate or loperamide (no = 0, yes = 1) x 30
Abdominal mass (no = 0, questionable = 1, present = 5) x 10
Hematocrit (males: 47 – HT%, females: 42 – Ht% x 6
Weight (1 – weight / standard weight x 100). Add or subtract according to the sign x 1
Total
Chart 1.
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tis exists and sigmoidoscopy or barium enema findings 
are negative, colonoscopy with multiple biopsies can de-
termine the presence and severity of colon inflammation, 
as well as to allow the visualization of the mucosa of the 
terminal ileus. Colonoscopy with biopsy is also effective 
in the differential diagnosis between Crohn’s colitis and 
ulcerative rectocolitis, as well as in the evaluation of other 
forms of colitis (actinic, ischemic, and microscopic)14 (C)15 
(D). Even though endoscopic evaluation is not related with 
disease activity15 (D), colonoscopy evaluation of intestinal 
anastomosis can be related with the possibility of recur-
rence after surgical treatment10 (D). Histological studies of 
biopsies obtained by colonoscopy allows diagnostic proof, 
differential diagnosis between Crohn’s colitis and ulcer-
ative rectocolitis, as well as the diagnosis of dysplasia and 
cancer in cases of long-standing colitis15 (D).
MEASURING DISEASE ACTIVITY
Measuring the activity in Crohn’s disease can be di cult 
due to different location patterns, as well as the presence of 
complications6 (D). A standard indicator of disease activ-
ity does not exist. Somewhat objective parameters, such as 
suspension of corticotherapy or activity without surgical 
indication, can be used6 (D). Differentiation between ac-
tivity and remission can be done by the Crohn’s Disease 
Activity Index (CDAI), detailed in Chart 1.
The disease is considered in remission when the CDAI 
is below 150; mild to moderate, when the CDAI is between 
150 and 219; moderate to severe, when the CDAI is be-
tween 220 and 450; and severe or fulminating, when the 
CDAI is above 450.
TREATMENT
Treatment is not indicated for asymptomatic patients or 
those in remission and who never underwent surgical 
treatment6 (D). Recommendations for clinical or surgical 
intervention result from location of the disease, severity, 
response to prior drug therapy, and diagnosis of complica-
tions. The initial objective of clinical treatment is to induce 
remission. Patients in remission should be considered for 
maintenance treatment. Symptomatic patients and those 
undergoing corticotherapy or with fever, vomiting, ab-
dominal pain, or suspected bowel obstruction or malnu-
trition should be hospitalized6 (D).
Surgical treatment of Crohn’s disease by resection or 
enteroplasty is indicated for complications and when clin-
ical intractability of refractory disease is indentified. For 
patients with perianal disease, drainage of abscesses is in-
dicated, as well as fistulotomy or drainage seton in more 
symptomatic cases. Proctectomy is indicated for cases of 
severe suppuration associated with severe proctitis and 
anal incontinence1 (C). 
ENTERITIS AND ILEOCECAL INVOLVEMENT
Ileal or ileocecal disease should be treated by the adminis-
tration of oral aminosalicylate (mesalazine, 3 to 4 g/day)16-18 
(A). Ileocecal disease can be treated with oral sulfasala-
zine, 1 to 4 g/day19 (A). Alternatively, oral ciprofloxacin, 
1 g/day, can be used for at least 6 weeks, and ideally from 
3 months to 1 year20 (A). For patients with ileocecal dis-
ease who do not respond to aminosalicylates, treatment 
with oral metronidazole, 10 to 20 mg/kg, can be offered 
for a maximum of 4 months21 (A) to try to postpone the 
introduction of corticotherapy. Evidence indicates that the 
combination of ciprofloxacin and metronidazole can pro-
duce results superior than each drug alone22 (B).
For patients with little or no response after the initial 
therapy with aminosalicylates (or alternatively, antibiot-
ics), corticotherapy should be instituted with oral predni-
sone, 40 to 60 mg/day19 (A). Oral budesonide, 9 mg/day, 
can be used instead of prednisone23 (A).
Immunosuppressive therapy in Crohn’s disease is in-
dicated in patients dependent on corticosteroids or those 
refractory to corticotherapy. Oral azathioprine and 6-mer-
captopurine are used in doses of 2 to 2.5 mg/kg/day and 
1 to 1.5 mg/kg/day, respectively. Their effectiveness in in-
ducing remission has been proven; however, they should 
be used for at least 4 months to classify the response24 (A). 
There is no recommendation on the duration of treatment. 
The use of immunosuppressors requires some experience, 
and leukocyte count should be done at the end of the first 
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week of treatment to detect hematologic toxicity of mer-
captopurine metabolites. Complete blood count and liver 
function tests should be done every 45 days, in the begin-
ning of treatment, and later every 3 months.
Biologic therapy with infliximab has been approved by 
the FDA (Food and Drug Administration) for induction 
and maintenance of remission in patients with Crohn’s dis-
ease, with moderate to severe activity, who had inadequate 
response to conventional therapy. In three doses of 5 mg/
kg, it is effective in inducing remission25 (A), and also the 
dose of 5 mg/kg every 8 weeks, for maintenance26 (A).
COLITIS
Clinical treatment should be initiated with oral sulfasala-
zine, 1 to 4 g/day. Oral mesalazine, in the dose of 1 to 4 g/
day, should be used in cases of sulfasalazine intolerance27 
(B). For individuals who do not respond to aminosalicy-
lates, oral prednisone, 20 to 60 mg/day, should be added19 
(A). In association with immunosuppressors, infliximab, 
three doses of 5 mg/kg, is effective for inducing remission25 
(A) and, for maintenance, 5 mg/kg every 8 weeks28 (A).
MAINTENANCE THERAPY
Indication of maintenance therapy in Crohn’s disease should 
be determined case by case. Maintenance therapy seems 
specially indicated in patients whose remission required 
corticotherapy, those who evolved with early symptomatic 
relapse after induction of remission, and also for those who 
underwent surgical treatment29 (B). For individuals with 
chronically active, steroid-dependent, or steroid refractory 
Crohn’s disease, azathioprine (oral, 2 to 2.5 mg/kg/day) or 
6-mercaptopurine (oral, 1 to 1.5 mg/kg/day), without ami-
nosalicylates, is beneficial after corticotherapy-induced 
remission30 (A). Evidence indicates the e cacy of oral sul-
fasalazine or mesalazine, in doses higher than 3.0 g/day, in 
preventing relapses after ileocolic resection31 .(A)
PERIANAL DISEASE
Anorectal abscess is treated by surgical drainage. Patients 
with plicomas, anal fissures, or fistulae with little suppura-
tion, should undergo clinical treatment1 (C). Oral metro-
nidazole, 20 mg/kg/day, divided in two doses, is indicated 
in the presence of fistulae, with a response rate higher than 
90%. Duration of treatment with metronidazole should 
not be higher than 4 weeks21 (A). Alternatively, oral cipro-
floxacin, 1 g/day, can be used for at least 6 weeks, and ide-
ally between 3 months and 1 year21 (A). Oral prednisone, 
20 to 60 mg/day, is indicated in case of little response to 
antibiotics, and it should be associated with them19 (A). To 
decrease the dose of prednisone or to discontinue cortico-
therapy, azathioprine (oral, 2 to 2.5 mg/kg/day) or 6-mer-
captopurine (oral, 1 to 1.5 mg/kg/day), results in healing of 
fistulae and symptomatic improvement, which is superior 
to placebo, and it can be used in association with antibiotic 
therapy. At least three months of treatment are required to 
evaluate response33 (A).
In patients with little or no response to antibiotics, 
corticosteroids, and immunosuppressors, intravenous in-
fliximab, 5 mg/kg, after two and six weeks (three doses) 
produces benefits when compared to placebo, with a mean 
duration of three months32 (A). Maintenance is achieved 
with a dose of 5 mg/kg every eight weeks and, if failure is 
observed, 10 mg/kg is effective28 (A).
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